New drug duo aims to reboot immune system against stubborn kidney cancer

NCT ID NCT06284564

Summary

This study is testing whether combining two drugs, evolocumab and nivolumab, can help control advanced kidney cancer that has stopped responding to standard immunotherapy or other targeted drugs. It will involve about 10 adults with metastatic kidney cancer to see if the combination is safe and can shrink or stabilize their tumors. The main goals are to measure tumor response and monitor side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.